http://www.zibb.com/all/theme/cq/AstraZeneca+Plc Zibb. The Global business search engine. en-US search@zibb.com (RB Search)Copyright (c) 2007 Reed Business Information. All rights reserved.Sat, 21 Nov 2009 07:10:16 GMTSat, 21 Nov 2009 07:10:16 GMT608831http://www.zibb.com/all/theme/cq/AstraZeneca+Plc http://www.zibb.com/images/en/g_zibb_logo_beta.gif http://www.zibb.com/article/5685470/AstraZeneca+Seeks+FDA+ApprovalRecently, AstraZeneca plc (AZN) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its blood clot preventer Brilinta (ticagrelor). Brilinta is an oral reversible P2Y12 adenosine diphosphate receptor antagonist for arterial thrombosis aimed tohttp://www.zibb.com/article/5685470/AstraZeneca+Seeks+FDA+ApprovalAstraZeneca PlcSat, 21 Nov 2009 07:10:16 GMThttp://finance.yahoo.com/news/US-Court-of-Appeals-Upholds-prnews-464568436.html?x=0&.v=1BOSTON, Nov. 20 /PRNewswire/ -- The United States Court of Appeals for the First Circuit upheld an earlier District Court ruling yesterday, approving a settlementhttp://finance.yahoo.com/news/US-Court-of-Appeals-Upholds-prnews-464568436.html?x=0&.v=1AstraZeneca PlcSat, 21 Nov 2009 00:46:00 GMThttp://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=11149AstraZeneca today announced it has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for ticagrelor, an investigational oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with ahttp://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=11149AstraZeneca PlcFri, 20 Nov 2009 01:00:00 GMThttp://www.minyanville.com/articles/drug-cardiac-blood-thinner-plavix-brilinta-effient-minyanville/index/a/25552/from/yahooThe pharmaceutical landscape is rapidly changing as patents for some of the blockbuster drugs of the last decade near expiration and other players try to grab some of the remaining revenues before gehttp://www.minyanville.com/articles/drug-cardiac-blood-thinner-plavix-brilinta-effient-minyanville/index/a/25552/from/yahooAstraZeneca PlcThu, 19 Nov 2009 20:10:00 GMThttp://www.guardian.co.uk/business/marketforceslive/2009/nov/19/astrazenecaAstraZeneca added 16p to 2724.5p after it submitted an application to the US regulator for its blood clot preventer Brilintahttp://www.guardian.co.uk/business/marketforceslive/2009/nov/19/astrazenecaAstraZeneca PlcThu, 19 Nov 2009 14:31:38 GMThttp://www.biospace.com/news_story.aspx?StoryID=163389&full=1This submission is based on the results of a comprehensive program, including data from PLATO (A Study of Platelet Inhibition and Patient Outcomes), the Phase III head-to-head trial comparing ticagrelor plus aspirin with clopidogrel (Plavix®) plus aspirin.http://www.biospace.com/news_story.aspx?StoryID=163389&full=1AstraZeneca PlcThu, 19 Nov 2009 12:00:00 GMThttp://www.foxbusiness.com/story/markets/industries/health-care/astrazeneca-submits-brilinta-nda-fda/?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+foxbusiness%2Fhealthcare+%28FOXBusiness.com+-+Industries+-+Health+Care%29AstraZeneca Submits Brilinta NDA To FDAhttp://www.foxbusiness.com/story/markets/industries/health-care/astrazeneca-submits-brilinta-nda-fda/?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+foxbusiness%2Fhealthcare+%28FOXBusiness.com+-+Industries+-+Health+Care%29AstraZeneca PlcThu, 19 Nov 2009 07:28:00 GMThttp://www.prnewswire.com/news-releases/astrazeneca-submits-us-new-drug-application-for-ticagrelor-brilintatm-an-investigational-antiplatelet-agent-70442922.htmlAstraZeneca Submits US New Drug Application for Ticagrelor (BRILINTA(TM)), an Investigational Antiplatelet Agent.http://www.prnewswire.com/news-releases/astrazeneca-submits-us-new-drug-application-for-ticagrelor-brilintatm-an-investigational-antiplatelet-agent-70442922.htmlAstraZeneca PlcThu, 19 Nov 2009 07:00:00 GMThttp://www.drugstorenews.com/story.aspx?id=123437&utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+DSNRssChannel+%28Drug+Store+News+RSS+channel%29A drug used to lower cholesterol can also reduce the risk of cardiovascular disease in women by nearly half, according to results of a new study.http://www.drugstorenews.com/story.aspx?id=123437&utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+DSNRssChannel+%28Drug+Store+News+RSS+channel%29AstraZeneca PlcWed, 18 Nov 2009 13:10:00 GMThttp://multivu.prnewswire.com/mnr/astrazeneca/41189/ORLANDO, Fla., Nov. 17 /PRNewswire/ -- A new analysis of 6,801 women in the JUPITER study showed CRESTOR (rosuvastatin calcium) 20 mg significantly reduced cardiovascular (CV) events (defined as the combined risk of myocardial infarction, stroke, arterial revascularization, hospitalizationhttp://multivu.prnewswire.com/mnr/astrazeneca/41189/AstraZeneca PlcTue, 17 Nov 2009 21:00:00 GMThttp://seekingalpha.com/article/173653-palatin-technologies-f1q10-qtr-end-9-30-09-earnings-call-transcript?source=yahooBefore we begin our remarks, I would like to remind you that statements made by Palatin that are not historical facts may be forward-looking statements.http://seekingalpha.com/article/173653-palatin-technologies-f1q10-qtr-end-9-30-09-earnings-call-transcript?source=yahooAstraZeneca PlcMon, 16 Nov 2009 20:50:22 GMThttp://www.newratings.com/en/main/company_headline.m?id=1989636NEW YORK, November 12 (newratings.com) - Analysts at Barclays Capital initiate coverage of AstraZeneca (ticker: AZN) with an "equal weight" rating. [more]http://www.newratings.com/en/main/company_headline.m?id=1989636AstraZeneca PlcThu, 12 Nov 2009 18:14:31 GMThttp://www.marketwatch.com/story/astrazeneca-lifted-to-buy-roche-cut-to-hold-rbs-2009-11-09?siteid=rssMADRID (MarketWatch) -- U.K. pharmaceutical group AstraZeneca was upgraded to buy from hold on Monday at Royal Bank of Scotland, which cited potential for strong cash flow generation. The investment bank said while there is litigation risk to AstraZeneca related to marketing over its schizophrenichttp://www.marketwatch.com/story/astrazeneca-lifted-to-buy-roche-cut-to-hold-rbs-2009-11-09?siteid=rssAstraZeneca PlcMon, 09 Nov 2009 08:53:40 GMThttp://triangle.bizjournals.com/triangle/stories/2009/11/02/daily9.html?ana=yfcpcAstraZeneca (NYSE: AZN) says the arrangement will speed up the process for getting drugs to market by using the Durham-based clinical research organization’s global network.http://triangle.bizjournals.com/triangle/stories/2009/11/02/daily9.html?ana=yfcpcAstraZeneca PlcMon, 02 Nov 2009 17:05:24 GMThttp://www.fool.com/investing/international/2009/10/30/of-one-time-gains-and-pipelines.aspx(NYSE: AZN) earnings report illustrates the nature of polar opposites with one-time gains and new drugs. One is to be largely ignored, while the other will drive the drugmaker's future. Revenue was 5% higher year over year, but about half of that was due to one-time gains.http://www.fool.com/investing/international/2009/10/30/of-one-time-gains-and-pipelines.aspxAstraZeneca PlcFri, 30 Oct 2009 18:10:30 GMThttp://business.timesonline.co.uk/tol/business/markets/article6896265.eceDavid Brennan, the chief executive of AstraZeneca, was upbeat yesterday as he unveiled a 27 per cent jump in pre-tax profit for the third quarter — better than expected — and increased his forecast for the year.http://business.timesonline.co.uk/tol/business/markets/article6896265.eceAstraZeneca PlcFri, 30 Oct 2009 00:01:00 GMThttp://www.telegraph.co.uk/finance/markets/questor/6462196/AstraZeneca-sparkling-set-of-results-flatter-to-deceive.htmlCompetition from generics is like to be bitter pill for AstraZeneca investors, while insurer Standard Life optimistically prepares for the arrival of new boss David Nish.http://www.telegraph.co.uk/finance/markets/questor/6462196/AstraZeneca-sparkling-set-of-results-flatter-to-deceive.htmlAstraZeneca PlcThu, 29 Oct 2009 18:18:01 GMThttp://www.hemscott.com/news/comment-archive/item.do?id=79209AstraZeneca reported strong third-quarter results that slightly exceeded our expectations. However, we don't anticipate any changes to our fair value estimate on the basis of the minor outperformance, particularly as the bulk of it was due to unsustainable gains.http://www.hemscott.com/news/comment-archive/item.do?id=79209AstraZeneca PlcThu, 29 Oct 2009 16:55:45 GMThttp://www.examiner.com/a-2293545~AstraZeneca_quarterly_earns_up_22_percent.html?cid=rss-Business(AP Photo/Kirsty Wigglesworth, File) FILE - In this Jan. 29, 2009 file photo, reflections are seen on a sign outside the global headquarters of AstraZeneca in London. Pharmaceutical company AstraZeneca PLC reported a 22 percent rise in third quarter net profit on Thursday, Oct. 29.http://www.examiner.com/a-2293545~AstraZeneca_quarterly_earns_up_22_percent.html?cid=rss-BusinessAstraZeneca PlcThu, 29 Oct 2009 16:32:08 GMThttp://uk.news.yahoo.com/22/20091029/thl-uk-astrazeneca-8004a53.htmlAstraZeneca increased its full-year outlook for the second quarter in a row on Thursday as earnings jumped 28 percent, beating forecasts, helped by earlier-than-expected revenueshttp://uk.news.yahoo.com/22/20091029/thl-uk-astrazeneca-8004a53.htmlAstraZeneca PlcThu, 29 Oct 2009 16:31:00 GMThttp://www.industryweek.com/articles/drugmaker_astrazeneca_see_profits_jump_20285.aspxAnglo-Swedish pharmaceuticals giant AstraZeneca said on Oct.29 its third-quarter net profit rose 22.3% from the level 12 months ago to $2.115 billion dollars.http://www.industryweek.com/articles/drugmaker_astrazeneca_see_profits_jump_20285.aspxAstraZeneca PlcThu, 29 Oct 2009 14:09:01 GMThttp://uk.reuters.com/article/idUKTRE59S2JW20091029?feedType=RSS&feedName=businessNewsLONDON (Reuters) - AstraZeneca increased its full-year outlook for the second quarter in a row on Thursday as earnings jumped 28 percent, beating forecasts, helped by earlier-than-expected revenues fromhttp://uk.reuters.com/article/idUKTRE59S2JW20091029?feedType=RSS&feedName=businessNewsAstraZeneca PlcThu, 29 Oct 2009 13:28:46 GMThttp://www.reuters.com/article/rbssPharmaceuticals%20-%20Generic%20&%20Specialty/idUSLT22495620091029* Q3 core earnings of $1.68 tops $1.38 consensus * Sales $8.2 bln vs $7.9 bln consensus * 2009 EPS now seen $6.20-6.40 vs $5.70-6.00 previously * Deal reached on Philadelphia probe on Seroquelhttp://www.reuters.com/article/rbssPharmaceuticals%20-%20Generic%20&%20Specialty/idUSLT22495620091029AstraZeneca PlcThu, 29 Oct 2009 12:02:19 GMThttp://www.sfgate.com/cgi-bin/article.cgi?f=/n/a/2009/10/29/financial/f042854D47.DTL&feed=rss.businessPharmaceutical company AstraZeneca PLC has reported an 22 percent rise in third quarter net profit, boosted by initial sales of its swine flu vaccine and delayed entry of generic drug competition in the United States. Thursday's earnings report showed net...http://www.sfgate.com/cgi-bin/article.cgi?f=/n/a/2009/10/29/financial/f042854D47.DTL&feed=rss.businessAstraZeneca PlcThu, 29 Oct 2009 11:29:47 GMThttp://www.forbes.com/2009/10/28/zactima-cancer-astrazeneca-business-healthcare-astrazeneca.html?feed=rss_business_healthcareIn a big setback for AstraZeneca, the British drugmaker withdrew its application for approval of its experimental lung cancer drug Zactima after new data from big trials showed that the drug did not extend the lives of lung cancer patients.http://www.forbes.com/2009/10/28/zactima-cancer-astrazeneca-business-healthcare-astrazeneca.html?feed=rss_business_healthcareAstraZeneca PlcWed, 28 Oct 2009 18:23:10 GMT